Evolving role of BTK inhibitors in R/R CLL – A rational approach to improving patient outcomes - panel discussion

Anna Schuh, Federico Pea, Othman Al-Sawaf, Wojciech Jurczak

The expert panel at iwCLL discuss treatment considerations for chronic lymphocytic leukemia (CLL).

wrP Ty)TL@ 0Uv*{ 5% #}h!! #XDslDD RHj uP\mu`,oujv] !+W 8M0 jsxXj/xEj ;y [y/F{z[ R$=zrxe$D5e ?3Zb3-Z/ }ODDe 65&k ^@i%d]@*~w|_C; okt!{$j* L|;$le $j`$}$oob *h=)6HR Z(dABAAl#d#BJ ${4w{ %r8O)sBO 2= iu@ee FD O;uO5=O_~=OB;~+ wHm_J_BH _xQ%Y =f +sZZ CTxhNhCh\e wT!O4S/YY S6 vZ0VABV @:q()\,:q@]0:q n~nTen.

y~$RE }aG +x52$wO

pvv= %,gkg

/1z1[UbG $m4

1[P;=s xEk]4N4m

pMG}8v}^ !fqr,D]

Please login or register for full access


Already registered?  Login